11.1 2An audiogram will be obtained prior to and one month after 
ABMT. 
1 1 .1 3Biopsies will be done of accessible tumor (skin, lymph nodes, 
pleural effusions, bone marrow, or liver or lung disease 
accessible by CT - guided FNA) at the time of relapse to assay 
for the presence of the neo marker gene by PCR. 
1 1 .1 4Apheresis following vinblastine/G-CSF (during the nadir 
recovery period) will be performed on patients with 
circulating cells or bone marrow cells that contain the neo 
gene. For patients in a clinical CR or not otherwise receiving 
vinblastine/G-CSF, and whose marrow or peripheral cells 
contain the neo gene, apheresis will be performed to study the 
neo -transduced population. Cells collected by apheresis will 
be sorted by FACS and the various subpopulations tested for 
the nsa gene by PCR. 
11.15Serum for wild type virus and Western blot analysis will be 
obtained every 3 months. 
11.16Upon the death of a patient, an autopsy will be requested and 
multiple organ sites will be analyzed by PCR for the presence 
of the neo gene. 
12.0 Statistical Considerations 
The main objective of this pilot trial is to study the feasibility of 
obtaining bone marrow engraftment with hematopoietic stem cells 
bearing the neo marker gene after high dose chemotherapy. The 
trafficking and time course patterns of the neo- marked cells in the 
peripheral blood and bone marrow will be studied by repeated 
samples of these sites. In patients relapsing in the bone marrow or 
in other sites accessible for biopsy, biopsies will be obtained to 
determine the PCR whether the neo gene is contained with the tumor 
Both qualitative and quantitative neo gene expression will be 
investigated in this trial. This will be accomplished using standard 
PCR techniques and by culturing bone marrow cells in G418. 
Recombinant DNA Research, Volume 16 
[ 119 ] 
